Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where James O McNamara is active.

Publication


Featured researches published by James O McNamara.


The New England Journal of Medicine | 1985

Comparison of Carbamazepine, Phenobarbital, Phenytoin, and Primidone in Partial and Secondarily Generalized Tonic–Clonic Seizures

Richard H. Mattson; Joyce A. Cramer; Joseph F. Collins; Dennis B. Smith; Delgado-Escueta Av; T. R. Browne; Peter D. Williamson; David M. Treiman; James O McNamara; Charlotte B. McCutchen

We conducted a 10-center, double-blind trial to compare the efficacy and toxicity of four antiepileptic drugs in the treatment of partial and secondarily generalized tonic-clonic seizures in 622 adults. Patients were randomly assigned to treatment with carbamazepine, phenobarbital, phenytoin, or primidone and were followed for two years or until the drug failed to control seizures or caused unacceptable side effects. Overall treatment success was highest with carbamazepine or phenytoin, intermediate with phenobarbital, and lowest with primidone (P less than 0.002). Differences in failure rates of the drugs were explained primarily by the fact that primidone caused more intolerable acute toxic effects, such as nausea, vomiting, dizziness, and sedation. Decreased libido and impotence were more common in patients given primidone. Phenytoin caused more dysmorphic effects and hypersensitivity. Control of tonic-clonic seizures did not differ significantly with the various drugs. Carbamazepine provided complete control of partial seizures more often than primidone or phenobarbital (P less than 0.03). Overall, carbamazepine and phenytoin are recommended drugs of first choice for single-drug therapy of adults with partial or generalized tonic-clonic seizures or with both.


Nature Biotechnology | 2006

Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras

James O McNamara; Eran R. Andrechek; Yong Wang; Kristi D. Viles; Rachel E. Rempel; Eli Gilboa; Bruce A. Sullenger; Paloma H. Giangrande

Technologies that mediate targeted delivery of small interfering RNAs (siRNAs) are needed to improve their therapeutic efficacy and safety. Therefore, we have developed aptamer-siRNA chimeric RNAs capable of cell type–specific binding and delivery of functional siRNAs into cells. The aptamer portion of the chimeras mediates binding to PSMA, a cell-surface receptor overexpressed in prostate cancer cells and tumor vascular endothelium, whereas the siRNA portion targets the expression of survival genes. When applied to cells expressing PSMA, these RNAs are internalized and processed by Dicer, resulting in depletion of the siRNA target proteins and cell death. In contrast, the chimeras do not bind to or function in cells that do not express PSMA. These reagents also specifically inhibit tumor growth and mediate tumor regression in a xenograft model of prostate cancer. These studies demonstrate an approach for targeted delivery of siRNAs with numerous potential applications, including cancer therapeutics.


Trends in Pharmacological Sciences | 1990

Excitatory amino acid receptors in epilepsy

Raymond Dingledine; Chris J. McBain; James O McNamara

Excitatory amino acid transmitters participate in normal synaptic transmission throughout the CNS (see Headley and Grillner, May TiPS), so it comes as no surprise that such excitatory pathways are involved in the initiation of seizures and their propagation. Most attention has been directed to synapses using NMDA receptors, although more recent evidence indicates potential roles for the AMPA receptors as well. In this article--the first of two to focus on the neurological dangers inherent in excitatory amino acid pathways--Raymond Dingledine, Chris McBain and James McNamara consider their involvement in epilepsy; next months article will cover brain damage following ischemia and hypoxia.


Neuron | 1997

Mutant mice and neuroscience: Recommendations concerning genetic background

Alcino J. Silva; Elizabeth Simpson; Joseph S. Takahashi; Hans Peter Lipp; Shigetada Nakanishi; Jeanne M. Wehner; Karl Peter Giese; Tim Tully; Ted Abel; Paul F. Chapman; Kevin Fox; Seth G. N. Grant; Shigeyoshi Itohara; Richard Lathe; Mark Mayford; James O McNamara; Roger J. Morris; Marina R. Picciotto; John C. Roder; Hee Sup Shin; Paul A. Slesinger; Daniel R. Storm; Michael P. Stryker; Susumu Tonegawa; Yanyan Wang; David P. Wolfer

The following scientists made significant contributions to the recommendations in this article:


Neuron | 2009

Remote Control of Neuronal Activity in Transgenic Mice Expressing Evolved G Protein-Coupled Receptors

Georgia M. Alexander; Sarah C. Rogan; Atheir I. Abbas; Blaine N. Armbruster; Ying Pei; John A. Allen; Randal J. Nonneman; John Hartmann; Sheryl S. Moy; Miguel A. L. Nicolelis; James O McNamara; Bryan L. Roth

Examining the behavioral consequences of selective CNS neuronal activation is a powerful tool for elucidating mammalian brain function in health and disease. Newly developed genetic, pharmacological, and optical tools allow activation of neurons with exquisite spatiotemporal resolution; however, the inaccessibility to light of widely distributed neuronal populations and the invasiveness required for activation by light or infused ligands limit the utility of these methods. To overcome these barriers, we created transgenic mice expressing an evolved G protein-coupled receptor (hM3Dq) selectively activated by the pharmacologically inert, orally bioavailable drug clozapine-N-oxide (CNO). Here, we expressed hM3Dq in forebrain principal neurons. Local field potential and single-neuron recordings revealed that peripheral administration of CNO activated hippocampal neurons selectively in hM3Dq-expressing mice. Behavioral correlates of neuronal activation included increased locomotion, stereotypy, and limbic seizures. These results demonstrate a powerful chemical-genetic tool for remotely controlling the activity of discrete populations of neurons in vivo.


Cell | 1998

Importance of the Intracellular Domain of NR2 Subunits for NMDA Receptor Function In Vivo

Rolf Sprengel; Bettina Suchanek; Carla Amico; Rossella Brusa; Nail Burnashev; Andrei Rozov; OØivind Hvalby; Vidar Jensen; Ole Paulsen; Per Andersen; Jeansok J. Kim; Richard F. Thompson; William Sun; Lorna C. Webster; Seth G. N. Grant; Jens Eilers; Arthur Konnerth; Jianying Li; James O McNamara; Peter H. Seeburg

NMDA receptors, a class of glutamate-gated cation channels with high Ca2+ conductance, mediate fast transmission and plasticity of central excitatory synapses. We show here that gene-targeted mice expressing NMDA receptors without the large intracellular C-terminal domain of any one of three NR2 subunits phenotypically resemble mice made deficient in that particular subunit. Mice expressing the NR2B subunit in a C-terminally truncated form (NR2B(deltaC/deltaC) mice) die perinatally. NR2A(deltaC/deltaC) mice are viable but exhibit impaired synaptic plasticity and contextual memory. These and NR2C(deltaC/deltaC) mice display deficits in motor coordination. C-terminal truncation of NR2 subunits does not interfere with the formation of gateable receptor channels that can be synaptically activated. Thus, the phenotypes of our mutants appear to reflect defective intracellular signaling.


Neuron | 1996

Requirement for superoxide in excitotoxic cell death.

Manisha Patel; Brian J. Day; James D. Crapo; Irwin Fridovich; James O McNamara

We tested the pathogenic role of O2-) radicals in excitotoxic injury. Inactivation of the TCA cycle enzyme, aconitase, was used as a marker of intracellular O2- levels, and a porphyrin SOD mimetic was used to scavenge O2-. The selective, reversible, and SOD-sensitive inactivation of aconitase by known O2- generators was used to validate aconitase activity as a marker of O2- generation. Treatment of rat cortical cultures with NMDA, KA, or the intracellular O2- generator PQ2+ produced a selective and reversible inactivation of aconitase, which closely correlated with subsequent cell death produced by these agents. The SOD mimetic, but not its less active congener, attenuated both aconitase inactivation and cell death produced by NMDA, KA, and PQ2+. These results provide direct evidence implicating O2(-) generation in the pathway to excitotoxic injury.


Nature | 1999

Emerging insights into the genesis of epilepsy.

James O McNamara

Epilepsies are a diverse collection of brain disorders that affect 1–2% of the population. Current therapies are unsatisfactory as they provide only symptomatic relief, are effective in only a subset of affected individuals, and are often accompanied by persistent toxic effects. It is hoped that insight into the cellular and molecular mechanisms of epileptogenesis will lead to new therapies, prevention, or even a cure. Emerging insights point to alterations of synaptic function and intrinsic properties of neurons as common mechanisms underlying the hyperexcitability in diverse forms of epilepsy.


Neuropharmacology | 1988

Anticonvulsant and antiepileptogenic actions of MK-801 in the kindling and electroshock models

James O McNamara; R.D. Russell; L. Rigsbee; Douglas W. Bonhaus

The actions of MK-801, a noncompetitive antagonist at the N-methyl-d-aspartate subtype of excitatory amino acid receptor, were investigated on the development of kindling and on seizures in the electroshock and kindling models. The drug MK-801 potently and effectively suppressed the tonic hindlimb extension component of electroshock-induced seizures; it also suppressed both the electrophysiological and behavioral manifestations of the development of kindling. In contrast to its effects on electroshock-induced seizures and the development of kindling, MK-801 only partly reduced the duration of seizures in fully kindled animals and did not elevate the threshold for afterdischarge despite the use of a large dose, associated with profound untoward behavioral effects. Together with previous findings, these results support the idea that noncompetitive blockade of NMDA receptors markedly inhibits the development of kindling. The diminished effectiveness of MK-801 against kindled seizures suggests that MK-801 will not be a clinically-useful anticonvulsant against complex partial seizures.


Neuron | 2004

Conditional deletion of TrkB but not BDNF prevents epileptogenesis in the kindling model.

Xiao Ping He; Robert Kotloski; Serge Nef; Bryan W. Luikart; Luis F. Parada; James O McNamara

Epileptogenesis is the process whereby a normal brain becomes epileptic. We hypothesized that the neurotrophin brain-derived neurotrophic factor (BDNF) activates its receptor, TrkB, in the hippocampus during epileptogenesis and that BDNF-mediated activation of TrkB is required for epileptogenesis. We tested these hypotheses in Synapsin-Cre conditional BDNF(-/-) and TrkB(-/-) mice using the kindling model. Despite marked reductions of BDNF expression, only a modest impairment of epileptogenesis and increased hippocampal TrkB activation were detected in BDNF(-/-) mice. In contrast, reductions of electrophysiological measures and no behavioral evidence of epileptogenesis were detected in TrkB(-/-) mice. Importantly, TrkB(-/-) mice exhibited behavioral endpoints of epileptogenesis, tonic-clonic seizures. Whereas TrkB can be activated, and epileptogenesis develops in BDNF(-/-) mice, the plasticity of epileptogenesis is eliminated in TrkB(-/-) mice. Its requirement for epileptogenesis in kindling implicates TrkB and downstream signaling pathways as attractive molecular targets for drugs for preventing epilepsy.

Collaboration


Dive into the James O McNamara's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Lawrence C Katz

Howard Hughes Medical Institute

View shared research outputs
Top Co-Authors

Avatar

Douglas W. Bonhaus

United States Department of Veterans Affairs

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge